MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596835 | Name: SK&F 107260

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SK&F 107260 is an RGD-containing peptide, is a potent GP IIb/IIIa antagonist and a vitronectin antagonist.

Chemical Structure

SK&F 107260
SK&F 107260
CAS#136620-00-3

Theoretical Analysis

MedKoo Cat#: 596835

Name: SK&F 107260

CAS#: 136620-00-3

Chemical Formula: C26H31N7O6S2

Exact Mass: 601.1777

Molecular Weight: 601.69

Elemental Analysis: C, 51.90; H, 5.19; N, 16.30; O, 15.95; S, 10.66

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SK&F 107260; Skf 107260; Skf-107260; Skf107260;
IUPAC/Chemical Name
2-((7S,13S)-13-(3-guanidinopropyl)-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5H-dibenzo[c,p][1,2]dithia[5,8,11,14]tetraazacycloheptadecin-7-yl)acetic acid
InChi Key
YITSCMGHJOGUNC-ROUUACIJSA-N
InChi Code
InChI=1S/C26H31N7O6S2/c1-33-18(9-6-12-29-26(27)28)24(38)30-14-21(34)31-17(13-22(35)36)23(37)32-16-8-3-5-11-20(16)41-40-19-10-4-2-7-15(19)25(33)39/h2-5,7-8,10-11,17-18H,6,9,12-14H2,1H3,(H,30,38)(H,31,34)(H,32,37)(H,35,36)(H4,27,28,29)/t17-,18-/m0/s1
SMILES Code
O=C([C@@H](N1C)CCCNC(N)=N)NCC(N[C@@H](CC(O)=O)C(Nc2ccccc2SSc3ccccc3C1=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 601.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wong A, Hwang SM, Johanson K, Samanen J, Bennett D, Landvatter SW, Chen W, Heys JR, Ali FE, Ku TW, Bondinell W, Nichols AJ, Powers DA, Stadel JM. Binding of [3H]-SK&F 107260 and [3H]-SB 214857 to purified integrin alphaIIbbeta3: evidence for a common binding site for cyclic arginyl-glycinyl-aspartic acid peptides and nonpeptides. J Pharmacol Exp Ther. 1998 Apr;285(1):228-35. PubMed PMID: 9536015. 2: Wong A, Hwang SM, McDevitt P, McNulty D, Stadel JM, Johanson K. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay. Mol Pharmacol. 1996 Sep;50(3):529-37. PubMed PMID: 8794891. 3: Samanen J, Wilson G, Smith PL, Lee CP, Bondinell W, Ku T, Rhodes G, Nichols A. Chemical approaches to improve the oral bioavailability of peptidergic molecules. J Pharm Pharmacol. 1996 Feb;48(2):119-35. Review. PubMed PMID: 8935160. 4: Freed MI, Boike S, Zariffa N, Jorkasky DK. Effect of acetylsalicylic acid on inhibition of ex vivo platelet aggregation and secretion by SKF 107260, a novel GPIIb/IIIa receptor antagonist. Thromb Haemost. 1994 Oct;72(4):622-6. PubMed PMID: 7878642. 5: Bondinell WE, Keenan RM, Miller WH, Ali FE, Allen AC, de Brosse CW, Eggleston DS, Erhard KF, Haltiwanger RC, Huffman WF, et al. Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Bioorg Med Chem. 1994 Sep;2(9):897-908. PubMed PMID: 7712125. 6: Ali FE, Bennett DB, Calvo RR, Elliott JD, Hwang SM, Ku TW, Lago MA, Nichols AJ, Romoff TT, Shah DH, et al. Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation. J Med Chem. 1994 Mar 18;37(6):769-80. PubMed PMID: 8145226.